Clinical Immunology and Immunopathology
Volume 31, Issue 1, April 1984, Pages 109-117
Interleukin 2 deficiencies in rheumatoid arthritis and systemic lupus erythematosus☆
References (30)
- et al.
Clin. Immunol. Immunopathol.
(1976) - et al.
Oral Surg. Oral Med. Oral Pathol.
(1975) - et al.
Nature (London)
(1977) - et al.
J. Immunol.
(1981) - et al.
J. Exp. Med.
(1981) - et al.
J. Clin. Invest.
(1980) - et al.
Clin. Exp. Immunol.
(1979) - et al.
Ann. Rheum. Dis.
(1981) - et al.
Arthritis Rheum.
(1976)
Bull. Rheum. Dis.
(1971)
Bull. Rheum. Dis.
(1958)
N. Engl. J. Med.
(1970)
J. Exp. Med.
(1981)
J. Immunol.
(1978)
Cited by (132)
Immunogenetic markers as prognostic tools for the management of various human diseases
2022, Immunogenetics: a Molecular and Clinical Overview: Clinical Applications of Immunogenetics, Volume IIIsolation, purification and identification of immunologically active peptides from Hericium erinaceus
2021, Food and Chemical ToxicologyCitation Excerpt :Nevertheless, not all immune enhancements are good. Excessive immune enhancement can lead to inflammation such as systemic lupus erythematosus, rheumatoid arthritis, kidney disease and allergic reactions (Hoffmann et al., 2000; Miyasaka et al., 1984). Unfortunately, these studies hardly indicate whether the active substance continues to produce pro-inflammatory effects on M1 macrophages.
Behcet's disease and complex aphthosis
1999, Journal of the American Academy of DermatologyDiminished production of type-I interferons and interleukin-2 in patients with multiple sclerosis
1997, Journal of the Neurological SciencesDefective production of interleukin-2 in patients with idiopathic Parkinson's disease
1995, Journal of the Neurological Sciences
- ☆
These studies were supported by the General Medical Research Service of the Veterans Administration.
Copyright © 1984 Published by Elsevier Inc.